$INTI
Inhibitor Therapeutics, Inc.

2021 Q1 Form 10-K Financial Statement

#000119312521095516 Filed on March 26, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 2019 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $163.9K $873.7K $294.6K
YoY Change -43.1% -43.26% -56.3%
% of Gross Profit
Research & Development $3.880K $185.3K $343.3K
YoY Change -96.02% -84.66% -47.62%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $167.8K $1.059M $637.9K
YoY Change -56.48% -61.46% -52.02%
Operating Profit -$167.8K -$1.059M
YoY Change -56.48% -61.46%
Interest Expense -$1.690K $1.070K $2.050K
YoY Change -264.08% -92.64% -38.25%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$127.8K -$1.058M -$635.8K
YoY Change -66.74% -61.3% -52.06%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$127.8K -$1.058M -$635.8K
YoY Change -66.74% -61.3% -52.06%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$340.40 -$2.844K -$1.716K
COMMON SHARES
Basic Shares Outstanding 375.9M 370.4M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $84.19K $75.06K $803.8K
YoY Change -72.19% -90.66% -27.5%
Cash & Equivalents $84.19K $75.06K $803.8K
Short-Term Investments
Other Short-Term Assets $36.79K $32.29K $42.45K
YoY Change -23.74% -23.93% 2.78%
Inventory
Prepaid Expenses $36.79K $42.45K
Receivables
Other Receivables
Total Short-Term Assets $121.0K $107.4K $846.3K
YoY Change -65.53% -87.31% -26.41%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $17.09K $24.41K $53.70K
YoY Change -63.16% -54.54% -35.29%
Total Long-Term Assets $17.09K $24.41K $53.70K
YoY Change -63.16% -54.54% -35.29%
TOTAL ASSETS
Total Short-Term Assets $121.0K $107.4K $846.3K
Total Long-Term Assets $17.09K $24.41K $53.70K
Total Assets $138.1K $131.8K $900.0K
YoY Change -65.25% -85.36% -27.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $322.0K $269.4K $315.9K
YoY Change 108.76% -14.72% -17.9%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $52.00K $30.04K $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $432.6K $425.4K $431.1K
YoY Change 25.07% -1.32% -38.47%
LONG-TERM LIABILITIES
Long-Term Debt $104.0K $66.56K $0.00
YoY Change
Other Long-Term Liabilities $3.000M $3.000M $3.000M
YoY Change 0.0% 0.0% 500.0%
Total Long-Term Liabilities $3.104M $3.067M $3.000M
YoY Change 3.47% 2.22% 500.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $432.6K $425.4K $431.1K
Total Long-Term Liabilities $3.104M $3.067M $3.000M
Total Liabilities $3.537M $3.492M $3.431M
YoY Change 5.7% 1.77% 185.77%
SHAREHOLDERS EQUITY
Retained Earnings -$57.35M -$55.91M
YoY Change 1.78% 5.54%
Common Stock $49.99M $49.42M
YoY Change 1.12% 0.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.399M -$3.360M -$2.531M
YoY Change
Total Liabilities & Shareholders Equity $138.1K $131.8K $900.0K
YoY Change -65.25% -85.36% -27.01%

Cashflow Statement

Concept 2021 Q1 2020 2019 Q4
OPERATING ACTIVITIES
Net Income -$127.8K -$1.058M -$635.8K
YoY Change -66.74% -61.3% -52.06%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$91.87K -$825.4K -$568.4K
YoY Change -81.67% -69.5% -31.7%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid $0.00
YoY Change -100.0%
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 101.0K 96.60K 0.000
YoY Change -95.98% -100.0%
NET CHANGE
Cash From Operating Activities -91.87K -825.4K -568.4K
Cash From Investing Activities
Cash From Financing Activities 101.0K 96.60K 0.000
Net Change In Cash 9.130K -728.8K -568.4K
YoY Change -101.82% 139.02% 71.13%
FREE CASH FLOW
Cash From Operating Activities -$91.87K -$825.4K -$568.4K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75059
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
803816
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
32292
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
42450
CY2020Q4 us-gaap Assets Current
AssetsCurrent
107351
CY2019Q4 us-gaap Assets Current
AssetsCurrent
846266
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
24408
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
53700
CY2020Q4 us-gaap Assets
Assets
131759
CY2019Q4 us-gaap Assets
Assets
899966
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
269416
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
315940
CY2020Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
100822
CY2019Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
100822
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
25124
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
14339
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
425406
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
431101
CY2020Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3000000
CY2019Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3000000
CY2020Q4 us-gaap Liabilities
Liabilities
3491962
CY2019Q4 us-gaap Liabilities
Liabilities
3431101
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
37364
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
37045
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
49814043
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
49384953
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-57172476
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55913999
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-3360203
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-2531135
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
131759
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
899966
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
185294
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1208075
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
873703
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1539821
CY2020 us-gaap Operating Expenses
OperatingExpenses
1058997
CY2019 us-gaap Operating Expenses
OperatingExpenses
2747896
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-1058997
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-2747896
CY2020 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1068
CY2019 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
14540
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-1057929
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-2733356
CY2020 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
200548
CY2019 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
200000
CY2020 inti Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-1258477
CY2019 inti Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-2933356
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
371927734
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
370432295
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
32351
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-728757
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-304897
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1108713
CY2020 us-gaap Stock Issued1
StockIssued1
200548
CY2019 us-gaap Stock Issued1
StockIssued1
99946
CY2019 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
269924
CY2019 us-gaap Dividends Preferred Stock
DividendsPreferredStock
200000
CY2020 us-gaap Dividends Preferred Stock
DividendsPreferredStock
200548
CY2020 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
228861
CY2020 us-gaap Profit Loss
ProfitLoss
-1057929
CY2019 us-gaap Profit Loss
ProfitLoss
-2733356
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
228861
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
269924
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-39450
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-28138
CY2020 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-35739
CY2019 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-270425
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-825357
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2705719
CY2019 inti Proceeds From Advances Of Royalties Related Party
ProceedsFromAdvancesOfRoyaltiesRelatedParty
2500000
CY2019 us-gaap Payments Of Dividends
PaymentsOfDividends
99178
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
96600
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2400822
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-222165
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-574005
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-45967
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-112934
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-13668
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
40085
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
281800
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
646854
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
742574
CY2019Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
736325
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
6608114
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
6425461
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
190515
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
339052
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
34231
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
33943
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
6060
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2742
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
7581494
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
7537523
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
7581494
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
7537523
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2019Q4 inti Percentage Of Deferred Tax Assets Valuation Allowance
PercentageOfDeferredTaxAssetsValuationAllowance
1.00
CY2020Q4 inti Net Operating Loss Amount Used To Offset Against Taxable Income
NetOperatingLossAmountUsedToOffsetAgainstTaxableIncome
35000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3424000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.28
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
14587
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1616842
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.15
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5002685
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.19
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1260
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13349461
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.10
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
14587
CY2020Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
8849461
CY2020Q4 inti Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Aggregate Intrinsic Value
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsAggregateIntrinsicValue
14587
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.03
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.05
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
2208685
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
4500000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
2208685
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
4500000
CY2020Q4 inti Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Exercise Price Per Share
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisePricePerShare
0.05
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
0
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001042418
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei No Trading Symbol Flag
NoTradingSymbolFlag
true
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020Q2 dei Entity Public Float
EntityPublicFloat
7400396
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
375876361
CY2020 dei Security12g Title
Security12gTitle
Common stock
CY2020 dei Entity Registrant Name
EntityRegistrantName
Inhibitor Therapeutics, Inc.
CY2020Q4 us-gaap Notes Payable To Bank Current
NotesPayableToBankCurrent
30044
CY2020Q4 us-gaap Notes Payable To Bank Noncurrent
NotesPayableToBankNoncurrent
11556
CY2020Q4 us-gaap Line Of Credit
LineOfCredit
55000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2253623
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2253623
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2020 inti Proceeds From Advances Of Royalties Related Party
ProceedsFromAdvancesOfRoyaltiesRelatedParty
0
CY2020 us-gaap Payments Of Dividends
PaymentsOfDividends
0
CY2020 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
41600
CY2020 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
55000
CY2020 us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
200548
CY2020 inti Royalty Rate On Net Sales
RoyaltyRateOnNetSales
0.09
CY2020 inti Description Of Royalty Payment
DescriptionOfRoyaltyPayment
With respect to each Advance made by Mayne Pharma prior to the receipt of FDA approval of an NDA for SUBA-Itraconazole BCCNS, each $0.75 increment of each such Advance will be credited and set off against each $1.00 increment of Royalty owed to the Company, and with respect to each Advance made by Mayne Pharma following the receipt of FDA approval of an NDA for SUBA-Itraconazole BCCNS, each $0.85 increment of each such Advance will be credited and set off against each $1.00 increment of Royalty owed to the Company.
CY2020 inti Fair Value Inputs Royalty Rate
FairValueInputsRoyaltyRate
0.70
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Estimates </div></div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2020Q4 inti Percentage Of Deferred Tax Assets Valuation Allowance
PercentageOfDeferredTaxAssetsValuationAllowance
1.00
CY2020 us-gaap Valuation Allowance Methodologies And Assumptions
ValuationAllowanceMethodologiesAndAssumptions
In accordance with GAAP, it is required that a deferred tax asset be reduced by a valuation allowance if, based on the weight of available evidence it is more likely than not (a likelihood of more than 50 percent) that some portion or all of the deferred tax assets will not be realized.
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
50270563
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.13
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P6M
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
373635873
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
370446185
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
373635873
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
370446185
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020 us-gaap Revenues
Revenues
0
CY2019 us-gaap Revenues
Revenues
0
CY2019 us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
99946
CY2020Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
0
CY2019 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0
CY2019 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0
CY2020 inti Accrued But Unpaid Dividends
AccruedButUnpaidDividends
100822
CY2019 inti Accrued But Unpaid Dividends
AccruedButUnpaidDividends
100822
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true

Files In Submission

Name View Source Status
0001193125-21-095516-index-headers.html Edgar Link pending
0001193125-21-095516-index.html Edgar Link pending
0001193125-21-095516.txt Edgar Link pending
0001193125-21-095516-xbrl.zip Edgar Link pending
d33379d10k.htm Edgar Link pending
d33379dex231.htm Edgar Link pending
d33379dex311.htm Edgar Link pending
d33379dex312.htm Edgar Link pending
d33379dex321.htm Edgar Link pending
d33379dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
inti-20201231.xml Edgar Link completed
inti-20201231.xsd Edgar Link pending
inti-20201231_cal.xml Edgar Link unprocessable
inti-20201231_def.xml Edgar Link unprocessable
inti-20201231_lab.xml Edgar Link unprocessable
inti-20201231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending